Acuren

Yahoo Finance • 4 days ago

TIC Solutions Announces Upcoming Participation in Baird's 2025 Global Industrial Conference

HOLLYWOOD, Fla., November 06, 2025--(BUSINESS WIRE)--TIC Solutions, Inc. (NYSE: TIC) (the "Company" or "TIC Solutions"), a leading provider of critical asset integrity solutions and tech-enabled, mission-critical Testing, Inspection, Certi... Full story

Yahoo Finance • last month

Acuren plans $250M private placement to existing investor

* Acuren (NYSE:TIC [https://seekingalpha.com/symbol/TIC]) plans to sell $250 million of the company’s securities in a private placement to an existing investor. * Pursuant to the terms of the agreement, the company will sell around 20.... Full story

Yahoo Finance • 2 months ago

Acuren Corporation (TIC): A Bull Case Theory

We came across a bullish thesis on Acuren Corporation on Kairos Research’s Substack. In this article, we will summarize the bulls’ thesis on TIC. Acuren Corporation's share was trading at $11.27 as of August 29th. TIC’s trailing and forwar... Full story

Yahoo Finance • 2 months ago

Five Below upgraded, Bill downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Telsey Advisory upgraded Five Below(FIVE... Full story

Yahoo Finance • 3 months ago

Acuren GAAP EPS of $0.00

* Acuren  press release [https://seekingalpha.com/pr/20200713-acuren-corporation-reports-results-for-the-second-quarter-2025] (NYSE:TIC [https://seekingalpha.com/symbol/TIC]): Q2 GAAP EPS of $0.00. * Delivered revenue of $313.9 million... Full story

Yahoo Finance • 3 months ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: iTeos Therapeutics, Inc. (Nasdaq - ITOS), ZimVie Inc. (Nasdaq - ZIMV), PharmChem, Inc. (OTC - PCHM), NV5 Global, Inc. (Nasdaq - NVEE)

BALA CYNWYD, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story